Literature DB >> 33779824

Impact of COVID-19 lockdown in patients with implantable cardioverter and cardiac resynchronization therapy defibrillators: insights from daily remote monitoring transmissions.

Giosuè Mascioli1, Elena Lucca2, Paola Napoli3, Daniele Giacopelli3,4.   

Abstract

In Italy, a strict lockdown was imposed from 8 March 2020 to stop the spread of the coronavirus disease 2019 (COVID-19). We explored the effect of this lockdown on data transmitted by remote monitoring (RM) of implantable cardioverter and cardiac resynchronization therapy defibrillators (ICDs/CRT-Ds). RM daily transmissions from ICDs and CRT-Ds were analyzed and compared in two consecutive 1 month frames pre and post-lockdown: period I (7 February-7 March 2020) and period II (8 March-7 April 2020). The study cohort included 180 patients (81.1% male, 63.3% ICDs and 36.7% CRT-Ds) with a median age of 70 (interquartile range 62-78) years. The median value of physical activity provided by accelerometric sensors showed a significant reduction between period I and II [13.1% (8.2-18.1%) versus 9.4% (6.3-13.8%), p < 0.001]. Eighty nine % of patients decreased their activity, for 43.3% the relative reduction was ≥ 25%. The mean heart rate decreased significantly [69.2 (63.8-75.6) bpm vs 67.9 (62.7-75.3) bpm, p < 0.001], but with greater reduction (≈3 beats/minute) in patients aged < 70 years. Resting heart rate and thoracic impedance showed minor variations. No differences were observed in device pacing % and arrhythmias. In cardiac patients, the lockdown imposed to contain COVID-19 outbreak significantly reduced the amount of physical activity and the mean heart rate. These side effects of in-home confinement quarantine should be taken in consideration for frail patients.

Entities:  

Keywords:  COVID-19; Cardiac resynchronization therapy; Implantable cardioverter defibrillator; Lockdown; Remote monitoring

Year:  2021        PMID: 33779824      PMCID: PMC8006504          DOI: 10.1007/s00380-021-01843-w

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


Introduction

In January 2020, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) was identified as the infectious agent responsible for the COVID-19 disease [1]. The first cases of COVID-19 infection were reported in the city of Wuhan (Hubei province, China) in December 2019 and rapidly grew in several countries worldwide [2]. On 30 January 2020, the World Health Organization (WHO) declared the outbreak of SARS-CoV-2 a “Public Health Emergency of International Concern” [3] and a pandemic situation on 11 March 2020 [4]. Due to the lack of specific treatment or vaccines for COVID-19, “lockdown” measures, including staying at home, movement and travel restrictions, physical distancing, school and workplace closures, were adopted in various countries to limit human-to-human transmission of the coronavirus [5]. Italy was one of the most-affected countries in Europe [6] and Bergamo, in the Lombardy region, among northern Italian cities worst-hit by the pandemic [7-9]. As of March 8, 2020, the Italian government imposed a lockdown of the Lombardy region and of the whole country on March 11, 2020 [10]. Despite the effectiveness of these protective measures in containing the virus spread [11, 12], careful attention should be paid to their impact on health condition of patients who are compelled to prolonged in-home confinement and isolation. Using remote monitoring (RM) technologies, heart failure patients implanted with cardiac implantable electronic devices can transmit automatically a broad spectrum of variables associated with the clinical status of the patient that can be used to improve healthcare delivery. We performed a retrospective analysis of RM data transmitted from patients with implantable cardioverter and cardiac resynchronization therapy defibrillators (ICDs and CRT-Ds) to investigate the effect of COVID-19 pandemic lockdown on the RM variables.

Materials and methods

Study objective

The aim of this exploratory data analysis was to investigate the impact of COVID-19 lockdown on the variables transmitted by ICDs and CRTDs in the cohort of patients followed using a daily RM technology at the Humanitas Gavazzeni hospital in Bergamo, Lombardy, Italy. For this purpose, we compared RM data in two consecutive time windows of 1 month indexed at the date of COVID-19 lockdown. This analysis was performed in accordance with the ethical standards of the Institutional Research Committee and with the 1964 Helsinki declaration and its later amendments. Before RM registration, all patients provided written informed consent including the use of RM data without any detail that might disclose the identity of subjects for clinical research purposes. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Home monitoring technology

The Home Monitoring® technology (BIOTRONIK SE & Co. KG, Berlin, Germany) is a RM system for cardiac implantable electronic devices characterized by automatic and daily transmissions of a broad spectrum of technical and clinical variables. These data that are commonly stored in the device memory are also transmitted via wireless to a secure data server (i.e. BIOTRONIK-HM Service Center) using a portable patient unit. Collected data can be accessed and reviewed by physicians through a protected website similarly to in-person device follow-ups.

Data analysis and statistics

The primary analysis was the assessment of variations of RM parameters, as a result of prolonged home stay and lifestyle changes, after the implementation of the COVID-19 lockdown on 8 March 2020. Two consecutive time windows of 1 month were considered: Period I: 7 February–7 March 2020 Period II: 8 March–7 April 2020 We analyzed the following variables: RM daily transmission rate defined as the % of days covered by successful RM transmission, physical activity provided by an accelerometric sensor, thoracic impedance (TI), mean heart rate (HR), resting heart rate (rHR), frequency of premature ventricular contractions (PVCs), atrial and right ventricular pacing percentage, CRT pacing %, HR variability, atrial fibrillation (AF) episodes, number of anti-tachycardia pacing (ATP) and high-energy shock delivered due to ventricular arrhythmias. Median values were calculated and compared between period I and period II with the Wilcoxon matched-pairs test or the two-sample proportion test as appropriate. Continuous variables were reported as median [interquartile range (IQR)] and binary or categorical variables as %. An additional analysis according to patient age was performed using the median age to define two subgroups of patients. Finally, a comparison of baseline characteristics between subgroups with different variation of physical activity (≥ 25 and < 25%) was performed. Between-group differences were tested with the Mann–Whitney U test for continuous variables and with Pearson χ2 test for binary variables. Statistical calculation was performed using the STATA version 11 software (StataCorp LP, College Station, TX, USA).

Results

Study cohort

Our study population included a total of 180 patients with at least one RM transmission both in Period I and II. Table 1 shows baseline clinical characteristics of the entire study cohort. Most patients were male (81.1%) with a median age of 70 (IQR 62–78) years (55% of the patients were aged ≥ 70 years). Patients with single chamber, dual chamber ICDs and CRT-Ds were 36.1%, 27.2% and 36.7%, respectively. The majority of patients was implanted for primary prevention (78.3%) and had ischaemic (47.2%) or dilated (23.3%) cardiomyopathy.
Table 1

Baseline population characteristics

Total(n = 180)
 Sex, male146 (81.1)
 Age (years)70 (62–78)
 ICD type
  Single chamber65 (36.1)
  Dual chamber49 (27.2)
  Biventricular66 (36.7)
 Indication for defibrillator
  Primary prevention141 (78.3)
  Secondary prevention37 (20.5)
  Other2 (1.1)
 Underlying heart disease
  Ischaemic cardiomyopathy85 (47.2)
  Dilated cardiomyopathy42 (23.3)
  Hypertrophic cardiomyopathy4 (2.2)
  Arrhythmogenic right ventricular dysplasia7 (3.9)
  Brugada14 (7.8)
  Valvular heart disease12 (6.7)
  Other12 (6.7)
  None4 (2.2)

Data are shown as median (interquartile range) and n (%) for binary variables

Baseline population characteristics Data are shown as median (interquartile range) and n (%) for binary variables

Impact on home monitoring variables

The results of the analyzed RM parameters on the overall population are reported in Table 2. The RM daily transmission rate was generally very high with a slight increase during COVID-19 lockdown [97% (IQR 93–100%) vs 97% (IQR 97–100%), p = 0.041]. The comparison of median values showed a significant reduction of physical activity [13.1% (IQR 8.2–18.1%) vs 9.4% (IQR 6.3–13.8%), p < 0.001]. The relative reduction of physical activity was of 21.6% (IQR 35.2–10.4%). Also, the mean HR decreased significantly [69.2 (IQR 63.8–75.6) bpm vs 67.9 (IQR 62.7–75.3) bpm, p < 0.001]. A less remarkable, but statistically significant, reduction of rHR and increase of TI were also observed (Table 2). No differences were found for the other parameters between the two time periods.
Table 2

Median values of daily remote monitoring transmissions in period I (1 month pre-lockdown) and II (1 month post-lockdown) in the entire study cohort (n = 180)

Period I (1 month pre-lockdown)Period II (1 month post-lockdown)p value
RM daily transmission rate (%)97.0 (93.0–100)97.0 (97.0–100)0.041
Physical activity (%)13.1 (8.2–18.1)9.4 (6.3–13.8)< 0.001
Thoracic impedance (Ohm)74.4 (66.5–80)74.9 (68.5–81)< 0.001
Mean heart rate (bpm)69.2 (63.8–75.6)67.9 (62.7–75.3)< 0.001
Resting heart rate (bpm)60 (54.3–66.2)59.8 (53.5–66.8)0.004
Frequency of PVCs (n/hour)2.2 (0–45.7)1.2 (0–41.2)0.298
Atrial pacing percentage (%)15.2 (0.3–47.8)13.2 (0.6–48.4)0.102
Right ventricular pacing percentage (%)1.3 (0–92.4)1.4 (0–92.8)0.853
CRT pacing percentage (%)98.6 (95.1–99.8)98.8 (96.6–100)0.183
PP variability (ms)83.5 (54.7–102.0)78.6 (57–101.8)0.143
Number of patients with AF episodes, n (%)18 (14.3)19 (15.1)0.859
24 h AF burden* (%)100 (2–100)100 (4.4–100)0.126
Number of patients with ATP, n (%)3 (1.7)3 (1.7)1.000
Number of patients with shock n (%)1 (0.6)3 (1.7)0.315

Data are shown as median (interquartile range) and n (%) for binary variables

RM remote monitoring, PVCs pre-ventricular contractions, CRT cardiac resynchronization therapy, AF atrial fibrillation, ATP anti-tachycardia pacing

aConsidering only patients with at least one AF episode

Median values of daily remote monitoring transmissions in period I (1 month pre-lockdown) and II (1 month post-lockdown) in the entire study cohort (n = 180) Data are shown as median (interquartile range) and n (%) for binary variables RM remote monitoring, PVCs pre-ventricular contractions, CRT cardiac resynchronization therapy, AF atrial fibrillation, ATP anti-tachycardia pacing aConsidering only patients with at least one AF episode

Age subgroups

Table 3 summarizes the analysis by age subgroup (i.e. < 70 and ≥ 70 years) between periods I and II. Patients aged less than 70 years had more consistent reductions of physical activity [≈5%, a median relative decrease of 23.1% (IQR 38–11.4%)], mean HR (≈3 beats/minute) and rHR (≈2 beats/minute). In addition, we observed a significant increase of atrial pacing percentage (≈2%) and TI (≈1 Ω). Young patients with at least one AF episode appeared also to increase the time spent in atrial arrhythmia [99.9% (IQR 0.4–100%) vs 99.9% (IQR 4.4–100%), p = 0.048]. In the subgroup of elderly patients, the reduction of physical activity [−19.3% (IQR 33–9.8%)] was significant, but less remarkable due to a lower baseline value [10.6% (IQR 6.7–16.2%)]. Mean HR, TI and CRT pacing percentage showed small increases, while no difference was found in rHR.
Table 3

Median values of daily remote monitoring transmissions in period I (1 month pre-lockdown) and II (1 month post-lockdown) in patients aged <70 years (n = 81) and aged ≥70 years (n = 99)

Patients aged < 70 yearsPatients aged ≥ 70 years
Period I (1 month pre-lockdown)Period II (1 month post-lockdown)p valuePeriod I (1 month pre-lockdown)Period II (1 month post- lockdown)p value
RM daily transmission rate (%)97.0 (88.5–100)97.0 (95.5–100)0.10997.0 (93.0–100)97.0 (97.0–100)0.177
Physical activity (%)16.1 (10.8–21.6)11.4 (8.6–15.2)< 0.00110.6 (6.7–16.2)8.2 (4.5–11.7)< 0.001
Thoracic impedance (ohm)74.5 (66.5–78.8)75.2 (69.0–79.5)< 0.00173.8 (66.3–80.5)74.6 (66.7–82.0)0.013
Mean heart rate (bpm)71.3 (65.1–78.8)68.1 (62.8–76.8)< 0.00167.2 (63.2–73.8)67.8 (62.0–74.0)< 0.001
Resting heart rate (bpm)60.2 (52.2–67.9)58.0 (52.1–66.1)< 0.00160.0 (54.6–65.4)60.0 (54.7–67.2)0.402
Frequency of PVCs (n/hour)0.4 (0–40.5)0.1 (0–31.6)0.3655.7 (0–68.7)1.6 (0.1–68.4)0.448
Atrial pacing percentage (%)8.9 (0.1–23)10.8 (0.4–30.7)0.01223.1 (0.5–57.8)18.3 (0.6–56.6)0.815
Right ventricular pacing percentage (%)0.3 (0–4.6)0.3 (0–4.4)0.69611.1 (0.2–97.2)10.5 (0.3–96.4)0.946
CRT pacing percentage (%)96.0 (95.1–99.8)98.7 (93.6–100)0.52898.6 (94.7–99.9)98.9 (96.7–100)0.048
PP variability (ms)93.9 (69.1–114.7)89.9 (71.6–112.7)0.12070.1 (36.5–86.7)70.9 (38.1–88.9)0.673
Number of patients with AF episodes n (%)7 (11.9)9 (15.2)0.59111 (16.7)10 (15.1)0.812
24 h AF burden*(%)99.9 (0.4–100)99.9 (4.4–100)0.048100 (17.5–100)100 (4.1–100)0.723
Number of patients with ATP n (%)1 (1.3)1 (1.3)1.0002 (2.1)2 (2.1)1.000
Number of patients with shock, n (%)1 (1.3)2 (2.5)0.5600 (0)3 (1.0)0.316

Data are shown as median (interquartile range) and n (%) for binary variables

RM remote monitoring, PVC pre-ventricular contraction, CRT cardiac resynchronization therapy, AF atrial fibrillation, ATP anti-tachycardia pacing

aConsidering only patients with at least one AF episode

Median values of daily remote monitoring transmissions in period I (1 month pre-lockdown) and II (1 month post-lockdown) in patients aged <70 years (n = 81) and aged ≥70 years (n = 99) Data are shown as median (interquartile range) and n (%) for binary variables RM remote monitoring, PVC pre-ventricular contraction, CRT cardiac resynchronization therapy, AF atrial fibrillation, ATP anti-tachycardia pacing aConsidering only patients with at least one AF episode Daily temporal trends indexed at lockdown date (time zero) of physical activity, TI, mean HR and rVHR in the overall population and subgroups are depicted in Fig. 1.
Fig. 1

Daily trends of remote monitoring variables during COVID-19 pandemic in the entire cohort (n = 180), in patients aged < 70 years (n = 81) and ≥ 70 years (n = 99). Time zero is the date of lockdown (8 March 2020)

Daily trends of remote monitoring variables during COVID-19 pandemic in the entire cohort (n = 180), in patients aged < 70 years (n = 81) and ≥ 70 years (n = 99). Time zero is the date of lockdown (8 March 2020)

Characteristics of patients with physical activity drop

Figure 2 shows % distribution of patients according to different levels of activity variation. Eighty nine % of patients decreased their activity during the lockdown period. Among them, 78 patients showed a relative reduction ≥ 25%. Patients with the most remarkable physical activity reduction were more likely to be men compared (94.9 vs 70.6%, p < 0.001) than the rest of the cohort, while no age differences were found (Table 4).
Fig. 2

Distribution of patients according to relative variation of median physical activity between the two consecutive 1 month time windows pre and post-lockdown

Table 4

Characteristics of patients by level of physical activity variation

Total (n = 180)Patients with activity variation ≥ 25% (n = 78)Others (n = 102)p value
Sex (male)146 (81.1)74 (94.9)72 (70.6) < 0.001
Age (years)70 (62–78)69.5 (60–77)71 (64–79)0.256

Data are expressed as median (interquartile range), and n (%) for binary variable

Distribution of patients according to relative variation of median physical activity between the two consecutive 1 month time windows pre and post-lockdown Characteristics of patients by level of physical activity variation Data are expressed as median (interquartile range), and n (%) for binary variable

Discussion

There are few studies on the effects of COVID-19 lockdown on people isolated at home for a prolonged period of time [13-17]. This very little literature highlighted several negative consequences of restrictive measures, such as physical inactivity, unhealthy diet, mental stress, anxiety and the resulting increased cardiovascular risk burden. To our knowledge, this is the first analysis that assessed the impact of COVID-19 lockdown on a wide range of health parameters of heart failure patients who were forced to spend an extended time at home. Our analysis demonstrated a relative reduction of 21.6% of physical activity in the overall population over a 1 month period after the lockdown date. Eighty nine % of patients experienced this effect and a ≥ 25% relative reduction was observed for 43.3% of them. In agreement with our findings, Malanchini et al. [14] showed a decrease in physical activity of more than 25% for a range of 45.9–57.2% of patients during the lockdown period. This is of utmost concern for heart failure patients considering the benefits of physical activity in primary and secondary prevention of cardiovascular disease [18]. The reduction in physical activity affected both patients aged less than 70 years and those aged ≥ 70 years. Moreover, our study showed that patients with marked physical activity reduction (i.e. ≥ 25%) were more likely men. This result might be explained by the fact that women are generally more physically inactive than men [19]. We observed an inactivity-induced decrease of both mean HR and rHR in the entire population in the first month since lockdown was implemented. As expected, younger patients were shown to have higher variations of heart rate as compared with the overall population. On the contrary, physical inactivity during the lockdown period has not affected rHR in the elderly. On the other hand, a significant increase of mean HR was observed in patients over 70 years of age during COVID-19 lockdown. These findings in the elderly could be explained by two main factors: (1) habitual lower levels of physical activity and (2) the effect of psychological stress resulting from social isolation and fear of getting infected. Stress-related effects on heart rate could be attenuated in young patients who were shown to have physically more active lifestyle. Consistently, Huang et al. [20] reported that subjects of higher fitness levels exhibit a lesser heart rate response to psychological stress. Finally, we observed statistically significant increase of thoracic impedance between period before and after the lockdown both in the overall population and in the age-subgroups. A plausible explanation for this finding might be the fibrotic pattern typical of the late stage of lung injury previously found in COVID-19 patients [21-23]. Indeed, despite we have no evidence of COVID-19 infection among analyzed patients, our results were drawn from people living in Bergamo, one of the hardest-hit cities by the pandemic in Italy. In this scenario, RM systems could be an ideal tool to continuously surveil health status and to verify adherence to lockdown in heart failure patients. Our findings suggested that most patients respected the strict lockdown measures.

Limitations

This analysis has some limitations that should be acknowledged. First, not all baseline patient information, such as medical history and medication, was available for a more complete description of the population. Second, the analysis included subjects from a limited geographical area whose lifestyle habits may differ from those of the general population. Finally, parameter variations were assessed only over limited observation periods to draw conclusions on long-term effects of COVID-19 lockdown. Nevertheless, there are scant data on the impact of lockdown on health parameters of cardiac patients, and therefore our analysis adds evidence on possible side effects of restrictive measures during a pandemic.

Conclusion

Our analysis explored the impact of COVID-19 lockdown on RM parameters in ICDs and CRT-Ds patients. In-home confinement quarantine caused a significant reduction not only of physical activity, but also of mean HR. In cardiac patients, the potential deleterious clinical effects of long-term lockdown may be carefully assessed and RM systems could be a valuable option for continuous health status surveillance.
  16 in total

Review 1.  Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated.

Authors:  Alberto J Alves; João L Viana; Suiane L Cavalcante; Nórton L Oliveira; José A Duarte; Jorge Mota; José Oliveira; Fernando Ribeiro
Journal:  World J Cardiol       Date:  2016-10-26

2.  A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression.

Authors:  Samuel B Polak; Inge C Van Gool; Danielle Cohen; Jan H von der Thüsen; Judith van Paassen
Journal:  Mod Pathol       Date:  2020-06-22       Impact factor: 7.842

3.  COVID-19 outbreak: impact of the quarantine-induced stress on cardiovascular disease risk burden.

Authors:  Anna Vittoria Mattioli; Milena Nasi; Camilla Cocchi; Alberto Farinetti
Journal:  Future Cardiol       Date:  2020-04-30

4.  Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease.

Authors:  Anna V Mattioli; Susanna Sciomer; Camilla Cocchi; Silvia Maffei; Sabina Gallina
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-05-30       Impact factor: 4.222

5.  A first estimation of the impact of public health actions against COVID-19 in Veneto (Italy).

Authors:  Dario Gregori; Danila Azzolina; Corrado Lanera; Ilaria Prosepe; Nicolas Destro; Giulia Lorenzoni; Paola Berchialla
Journal:  J Epidemiol Community Health       Date:  2020-05-04       Impact factor: 3.710

6.  Home Monitoring trends during COVID-19 infection.

Authors:  Vincenzo De Simone; Stefania Guardalben; Paola Guarise; Nicola Padovani; Daniele Giacopelli; Gabriele Zanotto
Journal:  J Arrhythm       Date:  2020-12-18

Review 7.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.

Authors:  Hussin A Rothan; Siddappa N Byrareddy
Journal:  J Autoimmun       Date:  2020-02-26       Impact factor: 7.094

8.  COVID-19 pandemic: the effects of quarantine on cardiovascular risk.

Authors:  Anna Vittoria Mattioli; Matteo Ballerini Puviani; Milena Nasi; Alberto Farinetti
Journal:  Eur J Clin Nutr       Date:  2020-05-05       Impact factor: 4.016

Review 9.  Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease.

Authors:  Mingzhi Li; Pinggui Lei; Bingliang Zeng; Zongliang Li; Peng Yu; Bing Fan; Chuanhong Wang; Zicong Li; Jian Zhou; Shaobo Hu; Hao Liu
Journal:  Acad Radiol       Date:  2020-03-20       Impact factor: 3.173

Review 10.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.

Authors:  Yixuan Wang; Yuyi Wang; Yan Chen; Qingsong Qin
Journal:  J Med Virol       Date:  2020-03-29       Impact factor: 20.693

View more
  3 in total

1.  "Unlocking Physical Activity" During COVID-19 in Cardiac Device Patients.

Authors:  Rebecca Harrell; Scarlett Anthony; Kevin Travia; Samuel F Sears
Journal:  J Cardiopulm Rehabil Prev       Date:  2022-06-10       Impact factor: 3.646

2.  Effects of COVID-19 lockdown on arrhythmias in patients with implantable cardioverter-defibrillators in southern Italy.

Authors:  Valentino Ducceschi; Marcello de Divitiis; Valter Bianchi; Raimondo Calvanese; Gregorio Covino; Antonio Rapacciuolo; Vincenzo Russo; Michelangelo Canciello; Mario Volpicelli; Giuseppe Ammirati; Raffaele Sangiuolo; Giovanni Papaccioli; Carmine Ciardiello; Sara Innocenti; Antonio D'Onofrio
Journal:  J Arrhythm       Date:  2022-04-12

3.  Impact of coronavirus disease (COVID-19) pandemic on physical activity of patients with cardiac implantable electronic devices-A remote monitoring study.

Authors:  Moritz T Huttelmaier; Alexander Gabel; Maria Seewald; Carsten Jungbauer; Stefan Frantz; Stefan Störk; Thomas H Fischer
Journal:  PLoS One       Date:  2022-08-12       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.